Ultragenyx Pharmaceutical (RARE) Invested Capital: 2016-2025
Historic Invested Capital for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $9.2 million.
- Ultragenyx Pharmaceutical's Invested Capital fell 97.36% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 97.36%. This contributed to the annual value of $255.3 million for FY2024, which is 7.30% down from last year.
- Ultragenyx Pharmaceutical's Invested Capital amounted to $9.2 million in Q3 2025, which was down 93.95% from $151.3 million recorded in Q2 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's Invested Capital peaked at $1.1 billion during Q1 2021, and registered a low of $9.2 million during Q3 2025.
- Its 3-year average for Invested Capital is $194.2 million, with a median of $151.3 million in 2025.
- Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 993.61% in 2024, then tumbled by 97.36% in 2025.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Invested Capital stood at $922.6 million in 2021, then slumped by 61.79% to $352.5 million in 2022, then decreased by 21.87% to $275.4 million in 2023, then declined by 7.30% to $255.3 million in 2024, then plummeted by 97.36% to $9.2 million in 2025.
- Its Invested Capital stands at $9.2 million for Q3 2025, versus $151.3 million for Q2 2025 and $144.2 million for Q1 2025.